ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

Tripathy, D, Tolaney, SM, Seidman, AD et al. (9 more authors) (2019) ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases. Future Oncology, 15 (19). pp. 2211-2225. ISSN 1479-6694

Abstract

Metadata

Authors/Creators:
  • Tripathy, D
  • Tolaney, SM
  • Seidman, AD
  • Anders, CK
  • Ibrahim, N
  • Rugo, HS
  • Twelves, C
  • Dieras, V
  • Müller, V
  • Tagliaferri, M
  • Hannah, AL
  • Cortés, J
Copyright, Publisher and Additional Information: © 2019 Debu Tripathy. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
Keywords: brain metastases; chemotherapy; etirinotecan pegol; metastatic breast cancer; NKTR-102
Dates:
  • Accepted: 17 April 2019
  • Published (online): 10 May 2019
  • Published: July 2019
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Clinical Cancer Research (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 28 Jun 2019 10:13
Last Modified: 15 Aug 2019 13:00
Status: Published
Publisher: Future Medicine
Identification Number: https://doi.org/10.2217/fon-2019-0180
Related URLs:

Download

Share / Export

Statistics